Torrent Pharma announces Q4 FY26 results

Ahmedabad: Torrent Pharmaceuticals Limited (‘’Company”) today announced its financial results for the fourth quarter of FY26.

Key Highlights for Q4 FY26:

• Revenue at Rs. 4,197 crores, up by 42% YoY
• Op. EBITDA* at Rs.1,356 crores, up by 41% YoY
• Op. EBITDA margin* at 32.3%; Gross Margin: 76%
• Net Profit after tax at Rs. 364 crores

Performance summary:

*Before exceptional items

Excluding JB Pharma, the Base business recorded revenue growth of 16% for the quarter and 15% for FY26, with operating EBITDA growth of 16% and margins of 32.7% for both periods. Details are as per Exhibit 1 below.

The Board has recommended a final dividend of Rs. 9/- per equity share of face value of Rs 5. 

Pursuant to the Acquisition of controlling stake in JB Pharma, the consolidated financial statements include the financial results of JB Pharma, its subsidiaries and acquisition effects from 21 January, 2026.

India:

• India business revenues at Rs 2,215 crores, were up 43%
• During the quarter, base business grew 15% vs IPM growth of 10% as per AIOCD PharmaTrac dataset
• For FY26, revenues at Rs 7,645 crores, were up by 20%
• Torrent’s base business continues to be amongst the fastest growing out of the top 10 companies
• Gx Semaglutide launch off to a strong start with 38% market share (oral + injectable combined) as per April 26 PharmaTrac data

Brazil:

• Brazil revenues at Rs 455 crores, were up by 30%.
• Constant currency revenues at R$ 259 million, were up by 11%.
• As per IQVIA, Torrent grew at 17% vs market growth of 6%; growth was aided by the performance of top brands & recent launches.
• Torrent has 58 products under ANVISA review.
• For FY26, revenues were Rs 1,362 crores, up by 24% (Constant currency revenue: R$ 823 million, up by 12%).

United States:

• US business revenues at Rs 396 crores, were up by 31%.
• Base business revenue grew by 16% (constant currency $38 million up by 9%)
• For FY26, revenues were Rs  1,363 crores, up by  24%
• Base business revenue for FY26 grew by 20% aided by performance of recent launches (constant currency $149 million up by 14%)

Germany:

• Germany revenues at Rs 333 crores, were up by 16%.
• Constant currency revenues at EUR 31 million, were down by 1%.
• Growth continued to be impacted due to supply disruption at a third party supplier.
• For FY26, revenues were Rs 1,249 crores, up by 10% (Constant currency revenue: EUR 122 million, down by 3%).

Exhibit 1: Base Business Performance

Share on Facebook

Post on X